Production (Stage)
Trinity Biotech plc
TRIB
$0.6341
-$0.0374-5.57%
NASDAQ
| 12/31/2024 | 06/30/2024 | 12/31/2023 | 09/30/2023 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -13.32% | 2.74% | -34.69% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -13.32% | 2.74% | -34.69% |
| Cost of Revenue | -- | -- | -21.06% | -7.67% | -17.45% |
| Gross Profit | -- | -- | 6.79% | 31.10% | -56.83% |
| SG&A Expenses | -- | -- | 13.22% | 59.53% | -10.96% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | 59.01% | -116.38% | 6,788.64% |
| Total Operating Expenses | -- | -- | -7.49% | 9.27% | -12.38% |
| Operating Income | -- | -- | -21.72% | -38.98% | -166.30% |
| Income Before Tax | -- | -- | 14.84% | -10.01% | -363.07% |
| Income Tax Expenses | -- | -- | 68.95% | 94.53% | -764.56% |
| Earnings from Continuing Operations | -- | -- | 14.61% | -13.60% | -354.59% |
| Earnings from Discontinued Operations | -- | -- | 493.26% | 187.46% | 6,334.48% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -- | 41.43% | 11.18% | -308.36% |
| EBIT | -- | -- | -21.72% | -38.98% | -166.30% |
| EBITDA | -- | -- | -31.14% | -47.02% | -150.64% |
| EPS Basic | -- | -- | 50.87% | 31.45% | -186.53% |
| Normalized Basic EPS | -- | -- | -6.98% | -6.98% | -222.50% |
| EPS Diluted | -- | -- | 50.88% | 31.27% | -180.64% |
| Normalized Diluted EPS | -- | -- | -6.98% | -6.98% | -222.50% |
| Average Basic Shares Outstanding | -- | -- | 17.39% | 26.35% | 40.58% |
| Average Diluted Shares Outstanding | -- | -- | 17.39% | 26.34% | 36.21% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |